His primary areas of investigation include Psychiatry, Alzheimer's disease, Internal medicine, Dementia and Placebo. Alzheimer's disease is the subject of his research, which falls under Disease. His Disease research is multidisciplinary, relying on both Natural history and Neuroscience.
His research on Internal medicine frequently connects to adjacent areas such as Surgery. His Dementia study combines topics in areas such as Pharmacotherapy, Confidence interval, Geriatrics and Quality of life. His Placebo research incorporates themes from Anesthesia, Galantamine, Central nervous system disease and Endocrinology.
Lon S. Schneider mostly deals with Disease, Psychiatry, Internal medicine, Clinical trial and Alzheimer's disease. His Disease study integrates concerns from other disciplines, such as Gerontology, Cognition, Neuroscience, Intensive care medicine and Biomarker. His Psychiatry study combines topics from a wide range of disciplines, such as Dementia and Clinical psychology.
Lon S. Schneider works mostly in the field of Internal medicine, limiting it down to topics relating to Placebo and, in certain cases, Randomized controlled trial, Adverse effect, Tolerability and Anesthesia, as a part of the same area of interest. His Clinical trial research is multidisciplinary, incorporating elements of Memantine, Physical medicine and rehabilitation, Cholinesterase, Drug development and Physical therapy. His Alzheimer's disease study incorporates themes from MEDLINE, Pharmacology, Cognitive disorder and Cognitive decline.
Disease, Clinical trial, Internal medicine, Alzheimer's disease and Dementia are his primary areas of study. His Disease research incorporates elements of Biomarker and Neuroimaging, Cognition, Neuroscience. His research integrates issues of Psychological intervention, Observational study, Physical medicine and rehabilitation and Adverse effect, Pharmacology in his study of Clinical trial.
In his research on the topic of Internal medicine, Tolerability is strongly related with Placebo. He has included themes like Psychiatry, Psychomotor agitation, Gerontology, Citalopram and Cognitive decline in his Alzheimer's disease study. Lon S. Schneider has researched Dementia in several fields, including MEDLINE, Intervention, Family medicine, Intensive care medicine and Cohort.
The scientist’s investigation covers issues in Disease, Alzheimer's disease, Dementia, Clinical trial and Internal medicine. His Disease research incorporates themes from Psychiatry, Cognition, Neuroscience, Intensive care medicine and Biomarker. His Psychiatry research is multidisciplinary, incorporating perspectives in Number needed to treat and Quality of life.
His research integrates issues of Placebo and Gerontology in his study of Alzheimer's disease. Lon S. Schneider has researched Clinical trial in several fields, including Adverse effect, Pharmacology, Urinary system and Randomized controlled trial. His work in Internal medicine tackles topics such as Oncology which are related to areas like Positron emission tomography.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Mary Sano;Christopher Ernesto;Ronald G. Thomas;Melville R. Klauber.
The New England Journal of Medicine (1997)
Dementia prevention, intervention, and care
Gill Livingston;Gill Livingston;Andrew Sommerlad;Vasiliki Orgeta;Sergi G Costafreda;Sergi G Costafreda.
The Lancet (2017)
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Bruno Dubois;Bruno Dubois;Howard H Feldman;Claudia Jacova;Harald Hampel;Harald Hampel.
Lancet Neurology (2014)
Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
Lon S. Schneider;Karen S. Dagerman;Philip Insel.
Common variants at MS4A4/MS4A6E , CD2AP , CD33 and EPHA1 are associated with late-onset Alzheimer's disease
Adam C. Naj;Gyungah Jun;Gary W. Beecham;Li-San Wang.
Nature Genetics (2011)
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Lon S. Schneider;Pierre N. Tariot;Karen S. Dagerman;Sonia M. Davis.
The New England Journal of Medicine (2006)
Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
Gary W. Small;Peter V. Rabins;Patricia P. Barry;Neil S. Buckholtz.
Diagnosis and Treatment of Depression in Late Life: Consensus Statement Update
Barry D. Lebowitz;Jane L. Pearson;Lon S. Schneider;Charles F. Reynolds.
A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease
Margaret J. Knapp;David S. Knopman;Paul R. Solomon;William W. Pendlebury.
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad;Bengt Winblad;Philippe Amouyel;Sandrine Andrieu;Clive Ballard.
Lancet Neurology (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: